csl ltd
ASLAN & CSL To Develop Asthma Treatment
ASLAN acquires license for CSL334, an anti-IL13 receptor monoclonal antibody for the treatment of asthma.
‘Dark-Horse’ Molecule Is A Potential Anti-Cancer Target
Australian researchers have identified a molecule called interleukin-11 as a potential new target for anti-cancer therapies.




